EVALUATION OF THE RESULTS OF CLINICAL EXAMINATION OF GROUPS OF PATIENTS WITH LUPUS NEPHRITIS
Keywords:
systemic lupus erythematosus, lupus nephritis, albuminuria, cholesterol, triglycerides, lipoproteins, glomerular filtration rate.Abstract
Currently, lupus nephritis (LN), which is caused by systemic lupus erythematosus, is considered one of the urgent problems of the medical and social health system due to high disability and mortality, and the number of such patients is increasing day by day. Despite advances in nephrology, lupus nephritis is one of the most common manifestations of systemic lupus erythematosus, where the incidence of the disease is 40-60%. The importance of hemodynamic, metabolic and genetic factors in the development of lupus nephritis is currently being discussed. The role of genetic factors that determine the development of lupus nephritis is being studied with great interest. But the clinical, pathogenetic and prognostic significance of genes in patients with HF have not been fully studied and there is no unambiguous answer to the question of the genetic predisposition that causes the development of HF. According to the conducted studies devoted to this problem, currently the assessment of the role of genes in the pathogenesis of LP development requires in-depth study.
References
Насонов ЕЛ, редактор. Системная красная волчанка. В кн.: Российские клинические рекомендации. Москва: ГЭОТАРМедиа; 2017. С. 113-41 [Nasonov EL, editor. Systemic lupus erythematosus. In: Rossiiskie klinicheskie rekomendatsii [Russian clinical guidelines]. Moscow: GEOTAR-Media; 2017. P. 113-41 (In Russ.)].
Костик М.М., Кучинская Е.М., Абдурагимова Ф.Н., Гурина О.П., Калашникова О.В., Часнык В.Г. Опыт применения ритуксимаба у детей с системной красной волчанкой: ретроспективное исследование серии случаев. Вопросы современной педиатрии. 2016; 15 (3): 295–300.
Weening J.J., D’Agati V.D., Schwartz M.M., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004;65:521-530.
Rovin B.H., Caster D.J., Cattran D.C., Gibson K.L., Hogan J.J., et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference Kidney Int 2019;95:281-295. doi: 10.1016/j.kint.2018.11.008.
Соловьев СК, Асеева ЕА, Зоткин ЕГ и др. Проблемы низкой активности и ремиссии при системной красной волчанке. Научно-практическая ревматология. 2019;57(2):218-21 [Soloviev SK, Aseeva EA, Zotkin EG, et al. Problems of low activity and remission in systemic lupus erythematosus. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(2):218-21 (In Russ.)]. doi: 10.14412/1995- 4484-2019-218-221.
Насонов ЕЛ, Авдеева АС. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019;57(4):452-61 [Nasonov EL, Avdeeva AS. Immunoinflammatory rheumatic diseases associated with type I interferon: new evidence. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(4):452-61 (In Russ.)]. doi: 10.14412/1995-4484-2019-452-461.
Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: A systematic review and Bayesian meta-analysis. Arthritis Rheum. 2016;68(6):1432-41. doi: 10.1002/art.39594.
